Tuesday, 29 November 2022, 18:28 HKT/SGT

Source: Eisai

TOKYO, Nov 29, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced that its application for a partial change to label for Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies (DLB) that was discovered and developed in-house, regarding dosage and administration for the treatment of DLB in Japan, has been approved today. (Please refer to "Notes to Editors" on the link below for details of the changes)

This partial change to label is based on the results of a reexamination for the indication of "suppression of progression of dementia symptoms in dementia with Lewy bodies" of this drug, which was categorized as Category 2.

After receiving approval for the partial change in dosage and administration for DLB, Eisai will continue to place the highest priority on the provision of proper use and safety information for this drug, and will make continued contributions to address the diversified needs of, and increase the benefits provided to people living with DLB and their families.

For more information visit www.eisai.com/news/2022/news202282.html.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network

Eisai

Dec 11, 2025 18:41 HKT/SGT

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

Dec 9, 2025 17:51 HKT/SGT

"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

Dec 4, 2025 17:36 HKT/SGT

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025

Dec 3, 2025 17:19 HKT/SGT

New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Dec 2, 2025 23:01 HKT/SGT

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025

Nov 28, 2025 22:00 HKT/SGT

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan

Nov 26, 2025 18:42 HKT/SGT

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Nov 17, 2025 21:08 HKT/SGT

"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

Oct 30, 2025 13:43 HKT/SGT

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

Oct 28, 2025 23:30 HKT/SGT

Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

More news >>

News Alerts


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Privacy Policy \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575

Connect With us: